Key facts
- MSInsight’s last known valuation is $3.1M (Oct 2024).
- It has raised $2.4M; the latest was Seed Round ($1.7M) in Mar 2025.
- Notable investors include Agoranov, BigBooster, Calyseed, Capital Cell, Finance & Technologie — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for MSInsight
- ·The full record, as it builds
Funding rounds
No funding rounds for MSInsight are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MSInsight
Developer of a bioinformatic system designed for the oncology market. The company's platform leverages next-generation sequencing data to provide actionable insights into microsatellite instability (MSI) status, a critical biomarker for cancer treatment, enabling healthcare professionals to make informed decisions about patient care by identifying potential treatment options, particularly immunotherapy, and improving overall patient outcomes.
- Sector
- Healthcare
- HQ
- Paris, France
- Employees
- 10
- Website
- msinsight.tech/
- Ownership
- Privately Held (backing)
MSInsight doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MSInsight shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MSInsight in its N-PORT filings yet. We sweep new filings monthly.